TF name : |
Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2)Kat5(ESA1,HTATIP,HTATIP1,PLIP,TIP,TIP60,ZC2HC5,cPLA2) |
TF experiment description: |
The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific.;The validation of several randomly selected ChIP-seq positive sites by ChIP-qPCR indicated specific Tip60 enrichments at these sites, when compared to control IgG ChIP signals and to background enrichment at an intergenic region negative for Tip60 binding (Fig.?1b).These results, together with the ChIP-qPCR validation (Fig.? 1b), indicate that the obtained anti-Tip60 ChIP-seq signal is specific. |